Optimized AAV to express the unfolded protein response transcription factor XBP1s ameliorates Alzheimer’s disease features in mouse models
Authors:
Preprint
Abstract
Proteostasis impairment at the level of the endoplasmic reticulum (ER) is a salient feature of Alzheimer’s disease (AD). The unfolded protein response (UPR) is the main pathway to cope with ER stress, where the expression of the transcription factor X-Box binding protein 1 (XBP1) is central to establish repair programs. To artificially enforce the adaptive capacity of the UPR in the AD brain, we recently reported the protective effects of overexpressing active XBP1 in the brain using adeno-associated vectors (AAVs) of AD mice, in addition to aged animals. Here we have generated a next generation vector suitable for clinical testing by (i) expressing codon-optimized human XBP1s without artificial tags, (ii) the use of the synapsin promoter to restrict expression to neurons, and (iii) incorporating a novel variant of AAV2 (AAV-TT) with greater biodistribution (here termed Proteostaser-1). Treatment of 5xFAD mice with Proteostaser-1 improved spatial learning and synaptic plasticity, and reduced the deposition of amyloid plaques in the brain. Proteostaser-1 administration also improved cognition in a model of sporadic AD based on the intracerebral injection of amyloid β oligomers. Our results further support the therapeutic potential of the UPR as a strategy to ameliorate AD features and sustain synaptic function.Keywords
Funding Information
- Agencia Nacional de Investigación y Desarrollo (ECOS230024)
- U.S. Army Medical Research and Development Command (AL2201415)
- U.S. Army Medical Research and Development Command (HT9425-23-1-0990)
- Agencia Nacional de Investigación y Desarrollo (ANID/NAM22I0057)
- Agencia Nacional de Investigación y Desarrollo (ANID/FONDECYT 3190596)
This publication has 65 references indexed in Scilit:
- From Lab Bench to Hope: Emerging Gene Therapies in Clinical Trials for Alzheimer’s DiseaseMolecular Neurobiology, 2024
- From lab bench to hope: a review of gene therapies in clinical trials for Parkinson’s disease and challengesNeurological Sciences, 2024
- Molecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s DiseaseMolecular Neurobiology, 2020
- Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-β oligomers in miceBrain, Behavior, and Immunity, 2017
- IRE1 signaling exacerbates Alzheimer’s disease pathogenesisActa Neuropathologica, 2017
- Nerve Growth Factor Gene TherapyJAMA Neurology, 2015
- The unfolded protein response in neurodegenerative diseases: a neuropathological perspectiveActa Neuropathologica, 2015
- The role of endoplasmic reticulum in amyloid precursor protein processing and trafficking: Implications for Alzheimer's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2014
- AAV-mediated delivery of the transcription factor XBP1s into the striatum reduces mutant Huntingtin aggregation in a mouse model of Huntington’s diseaseBiochemical and Biophysical Research Communications, 2012
- Protective effect against Parkinson's disease-related insults through the activation of XBP1Brain Research, 2009